Want to see AU:VLS full AI Analyst Report?
Top Page
Vita Life Sciences Limited
(Sydney:VLS)
Select Model
Select Model
Rating:74Outperform
Price Target:
AU$3.00
▲(19.05% Upside)
Action:Reiterated
Date:08/19/26
The score is primarily supported by strong financial performance (consistent growth, solid margins, and a low-debt balance sheet) and a reasonable valuation with an attractive dividend yield. These positives are partially offset by weak technical momentum signals (oversold readings and slightly negative MACD), which weigh on the near-term setup.
Positive Factors
Sustained Revenue Growth
Revenue has approximately doubled over five years, indicating durable product demand and expanding distribution. Continued growth across Australia and Asia can support operating scale, brand development and future earnings if the company maintains channel execution.
Negative Factors
Margin Compression
Lower profitability than earlier years suggests that costs, product mix or competitive pressures are absorbing part of the benefits from scale. Persistent compression could limit earnings growth even if revenue continues to expand.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Revenue has approximately doubled over five years, indicating durable product demand and expanding distribution. Continued growth across Australia and Asia can support operating scale, brand development and future earnings if the company maintains channel execution.
Read all positive factors
Vita Life Sciences Limited (VLS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$151.70M
Dividend Yield4.83%
Average Volume (3M)14.76K
Price to Earnings (P/E)13.9
Beta (1Y)0.02
Revenue Growth12.19%
EPS Growth22.36%
CountryAU
Employees400
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.20
Shares Outstanding54,371,357
10 Day Avg. Volume12,408
30 Day Avg. Volume14,758
Financial Highlights & Ratios
PEG Ratio0.72
Price to Book (P/B)2.57
Price to Sales (P/S)1.55
P/FCF Ratio9.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vita Life Sciences Limited Business Overview & Revenue Model
Company Description
Vita Life Sciences Limited is an Australian healthcare company specializing in the formulation, packaging, distribution, and sale of vitamins and nutritional supplements. The company's reach spans Australia, Singapore, Malaysia, Thailand, Vietnam,...
How the Company Makes Money
VLS makes money primarily by selling branded consumer health products (such as vitamins, minerals, supplements, and other wellness products) to customers through wholesale and direct-to-consumer channels. Its core revenue stream is product sales: ...
Vita Life Sciences Limited Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 96.03M | 93.27M | 79.50M | 74.16M | 66.89M | 57.10M |
| Gross Profit | 60.32M | 56.03M | 47.24M | 42.60M | 39.74M | 34.81M |
| EBITDA | 15.76M | 15.66M | 13.46M | 13.10M | 11.37M | 11.71M |
| Net Income | 11.15M | 10.44M | 8.78M | 9.08M | 7.08M | 8.29M |
Balance Sheet | ||||||
| Total Assets | 80.47M | 82.36M | 71.89M | 59.81M | 51.80M | 45.27M |
| Cash, Cash Equivalents and Short-Term Investments | 33.70M | 35.56M | 28.60M | 24.63M | 15.69M | 15.89M |
| Total Debt | 2.16M | 2.39M | 517.00K | 387.00K | 601.00K | 373.00K |
| Total Liabilities | 24.76M | 26.20M | 19.61M | 16.48M | 15.30M | 14.85M |
| Stockholders Equity | 55.81M | 56.25M | 52.35M | 43.40M | 36.57M | 30.75M |
Cash Flow | ||||||
| Free Cash Flow | 14.63M | 15.86M | 5.96M | 12.32M | 7.54M | 5.73M |
| Operating Cash Flow | 14.78M | 16.43M | 6.16M | 12.98M | 7.68M | 5.89M |
| Investing Cash Flow | -157.00K | -570.00K | -198.00K | -660.00K | -139.00K | -155.00K |
| Financing Cash Flow | -10.20M | -9.09M | -2.99M | -2.88M | -3.10M | -4.39M |
Vita Life Sciences Limited Technical Analysis
Positive
2.52
Price Trends
2.53
Positive
2.51
Positive
2.48
Positive
Market Momentum
0.08
Negative
71.24
Negative
98.39
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VLS, the sentiment is Positive. The current price of 2.52 is below the 20-day moving average (MA) of 2.59, below the 50-day MA of 2.53, and above the 200-day MA of 2.48, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 71.24 is Negative, neither overbought nor oversold. The STOCH value of 98.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:VLS.
Vita Life Sciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$151.70M | 13.95 | 19.91% | 4.33% | 12.19% | 22.36% | |
55 Neutral | AU$56.30M | -15.00 | -1.67% | ― | 15.21% | -141.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$2.90M | -0.33 | -76.30% | ― | 3.64% | -23.56% | |
48 Neutral | AU$4.98M | 0.31 | 93.89% | ― | -29.95% | ― | |
46 Neutral | AU$9.34M | -8.08 | -1301.30% | ― | 67.74% | 78.79% | |
39 Underperform | AU$18.68M | -5.07 | 4388.00% | ― | -53.90% | 57.52% |
* Healthcare Sector Average
AU:VLS
Vita Life Sciences Limited
2.79
0.57
25.51%
AU:EXL
Elixinol Wellness
0.02
>-0.01
-11.76%
AU:CAN
Cann Group
0.01
>-0.01
-16.67%
AU:EPN
Epsilon Healthcare Limited
0.02
>-0.01
-12.50%
AU:LGP
Little Green Pharma Ltd.
0.07
-0.05
-43.33%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-28.57%
Vita Life Sciences Limited Corporate Events
Vita Life Sciences Updates Investors on Ongoing Share Buy-Back Activity
Aug 18, 2026
Vita Life Sciences Limited, an ASX-listed life sciences company trading under the code VLS, maintains an active presence in the equity market through its ordinary fully paid shares. Its capital management decisions, particularly on-market buy-back...
Vita Life Sciences Highlights Expanding Healthcare Portfolio and Regional Focus
Aug 17, 2026
Vita Life Sciences Limited, an ASX-listed Australian healthcare company, focuses on over-the-counter medicines, complementary and alternative therapies, dietary supplements and health foods across Australia and South East Asia. Its products are de...
Vita Life Sciences Declares Interim Dividend for June 2026 Half-Year
Aug 17, 2026
Vita Life Sciences Limited has declared an interim dividend of AUD 0.05 per ordinary fully paid share for the six-month period ended 30 June 2026, reinforcing its commitment to returning capital to investors. The dividend will trade ex on 18 Septe...
Vita Life Sciences lifts half-year profit and raises interim dividend
Aug 17, 2026
Vita Life Sciences reported a 6.1% increase in revenue to A$48.3 million for the half year ended 30 June 2026, with profit before tax up 19.1% and net profit after tax rising 14.9% compared with the prior corresponding period. Net tangible assets ...
Vita Life Sciences Cancels Shares Following On-Market Buy-Back
Jul 2, 2026
Vita Life Sciences Limited has updated the market on a change to its issued capital following the cancellation of 10,427 ordinary fully paid shares. The cessation of these securities occurred on 2 July 2026 as a result of an on-market share buy-ba...
Vita Life Sciences Continues Incremental On-Market Share Buy-Back
Jun 29, 2026
Vita Life Sciences Limited has updated the market on its ongoing on-market share buy-back program, confirming that it repurchased a total of 10,424 ordinary fully paid shares prior to the most recent trading day. The latest daily notification repo...
Vita Life Sciences Continues On-Market Share Buy-Back Program
Jun 28, 2026
Vita Life Sciences Limited has continued its on-market share buy-back program for its ordinary fully paid shares, as disclosed in an updated notification to the ASX dated 29 June 2026. The company reported that a total of 10,000 shares had been re...
Vita Life Sciences Issues Cleansing Notice for New Incentive Plan Shares
Jun 18, 2026
Vita Life Sciences Limited has converted newly issued ordinary shares under its Long Term Incentive Plan, signalling ongoing use of equity-based remuneration for employees or executives. The company issued a cleansing notice confirming that these ...
Vita Life Sciences Boosts Director Stake with New LTIP Share Issuance
Jun 9, 2026
Vita Life Sciences Limited has updated the market on a change in director Andrew O’Keefe’s interests following the issuance of 600,000 new unquoted shares under the company’s Long Term Incentive Plan. The new LTIP shares, funded ...
Vita Life Sciences Issues 1.0m Unquoted Performance Shares Under Incentive Plan
Jun 9, 2026
Vita Life Sciences Limited has notified the market of the issue of 1,005,000 unquoted performance shares under its Long Term Incentive Plan. The new securities, which are not quoted and are subject to transfer restrictions, are being issued as par...
Vita Life Sciences Director Trims Indirect Shareholding
Jun 5, 2026
Vita Life Sciences has reported a change in the indirect shareholding of director Henry George Townsing following market trades conducted between 1 and 5 June 2026. Through entities associated with him, including Stanton Lea Pty Ltd as trustee for...
Vita Life Sciences Launches 15% On‑Market Share Buy‑Back
Jun 1, 2026
Vita Life Sciences Limited, a listed life sciences company with 54,231,784 shares on issue, serves the health and wellness market through products and services in the broader pharmaceutical and nutraceutical space. Its ASX listing positions it to ...
Vita Life Sciences Launches On-Market Share Buy-Back
Jun 1, 2026
Vita Life Sciences Limited, listed on the ASX under ticker VLS, has ordinary fully paid shares and operates in the broader life sciences sector, though this filing does not elaborate on its precise product portfolio or regional focus. The company ...
Vita Life Director Trims Indirect Shareholding in On-Market Trade
May 29, 2026
Vita Life Sciences Ltd has reported a change in the indirect shareholding of director Henry George Townsing following market trades conducted between 25 and 29 May 2026. Townsing disposed of 29,947 ordinary shares for total consideration of $72,22...
Vita Life Sciences Wins Shareholder Backing for AGM Resolutions
May 28, 2026
Vita Life Sciences Limited reported that all resolutions put to shareholders at its 2026 Annual General Meeting were passed, reflecting solid investor support for the board’s agenda. The meeting outcomes included approval of the remuneration...
Vita Life Sciences outlines governance focus at 2026 AGM
May 28, 2026
Vita Life Sciences Limited held its 2026 Annual General Meeting on 28 May, conducted as a hybrid event with shareholders able to attend in person at its office or observe via a webinar facility managed by Automic. The meeting was declared properly...
Vita Life Sciences Finalises A$2.45m On-Market Share Buy-Back
May 21, 2026
Vita Life Sciences Limited has completed its on-market share buy-back program of ordinary fully paid shares, initially announced in May 2025 and now formally closed with this final notification. The company repurchased 1,015,391 shares for a total...
Vita Life Sciences Cancels Shares Following On-Market Buy-Back
May 21, 2026
Vita Life Sciences Limited has announced the cessation of 2,400 ordinary fully paid shares from its issued capital on the ASX. The shares were cancelled following an on-market buy-back completed on 21 May 2026.This reduction in share capital margi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.